TY  - JOUR
T1  - Endocannabinoids Involvement in the Control of Eating Disorders
AU - Capasso, Anna AU - Milano, Walter 
JO  - Research Journal of Pharmacology
VL  - 12
IS  - 2-6
SP  - 6
EP  - 15
PY  - 2018
DA  - 2001/08/19
SN  - 1815-9362
DO  - rjpharm.2018.6.15
UR  - https://makhillpublications.co/view-article.php?doi=rjpharm.2018.6.15
KW  - Endocannabinoids
KW  -eating disorders
KW  -neurobiology
KW  -eating
KW  -alteration
KW  -drug
AB  - Eating Disorder (ED) is a syndrome characterized by persistent alteration of eating behavior and the
conditions that cause an insufficient ingestion and/or adsorption of foods. There are 3 different ED diseases;
Anorexia Nervosa (AN) Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions
that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal and social
factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic,
serotoninergic and peptidergic systems. In this respect while serotonin, dopamine and prostaglandin promote
the ingestion of food by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food
ingestion thus causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants
such as selective serotonin reuptake inhibitors and tricyclic antidepressant. Additionally, mood stabilizers
(lithium) anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in
the treatment of ED. Several studies indicate that the endocannabinoid system is involved in ED supporting
the idea that the cannabinoid signalling system is a key modulatory element in the activity in the brain area
associated with ED.
ER  -